Počet záznamů: 1  

Suppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II

  1. 1.
    SYSNO ASEP0324996
    Druh ASEPJ - Článek v odborném periodiku
    Zařazení RIVJ - Článek v odborném periodiku
    Poddruh JČlánek ve WOS
    NázevSuppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II
    Překlad názvuPotlačení nádorového růstu in vivo mitokanem alfa-tokoferylsukcinátem vyžaduje respirační komplex II
    Tvůrce(i) Dong, L.F. (AU)
    Freeman, R. (AU)
    Liu, J. (AU)
    Zobalová, Renata (BTO-N) RID
    Marin-Hernandez, A. (MX)
    Stantic, M. (AU)
    Rohlena, Jakub (BTO-N) RID
    Vališ, Karel (BTO-N)
    Rodriguez-Enriquez, S. (MX)
    Butcher, B. (AU)
    Goodwin, J. (AU)
    Brunk, U.T. (SE)
    Witting, P. K. (AU)
    Moreno-Sanchez, R. (MX)
    Scheffler, I.E. (US)
    Ralph, S.J. (AU)
    Neužil, Jiří (BTO-N) RID
    Zdroj.dok.Clinical Cancer Research - ISSN 1078-0432
    Roč. 15, č. 5 (2009), s. 1593-1600
    Poč.str.8 s.
    Jazyk dok.eng - angličtina
    Země vyd.US - Spojené státy americké
    Klíč. slovaSDHC-mutants ; mitocans ; mitochondrial complex II
    Vědní obor RIVEB - Genetika a molekulární biologie
    CEPGA204/08/0811 GA ČR - Grantová agentura ČR
    IAA500520702 GA AV ČR - Akademie věd
    CEZAV0Z50520701 - BTO-N (2007-2013)
    UT WOS000263851900013
    DOI10.1158/1078-0432.CCR-08-2439
    AnotaceMitochondrial complex II (CII) is emerging as an important target for the mitocan α-tocopheryl succinate (α-TOS) in selectively killing cancer cells. Here, we show that CII also has a major role in the anti-cancer efficacy of the vitamin E analogue in vivo using an animal model of cancer. Wild type, CII-defective (succinate dehydrogenase subunit C, SDHC-mutant) and CII-reconstituted Chinese hamster lung fibroblasts were transformed with H-Ras, and were used to establish xenograft tumours in nude mice. Growth of the SDHC-wild type and SDHC-reconstituted tumours was highly sensitive to α -TOS, whereas the CII-defective tumours were relatively resistant to the drug, assessed by monitoring tumour progression using ultrasound imaging. Since mutations in complex II occur very rarely in human cancers, agents like vitamin E analogues should be effective anti-cancer drugs, and this study provides support for their testing in clinical trials
    PracovištěBiotechnologický ústav
    KontaktMonika Kopřivová, koprivom@img.cas.cz, Tel.: 296 443 610
    Rok sběru2009